This marks the second indication for tirzepatide in just more than a year, following its November 2023 approval for adults with obesity or overweight and weight-related medical problems.
The 22.7% weight loss at 68 weeks places CagriSema essentially on par with, not superior to, competing antiobesity drugs including Lilly's tirzepatide.
When asked about her 3 wishes for the future of obesity care, Donna Ryan, MD, told Patient Care that she had just one: access.
Your daily dose of the clinical news you may have missed.
Your daily dose of the clinical news you may have missed.
The future of obesity medicine is filled with promise as GLP-1 RAs and other peptides continue to demonstrate pluripotency in metabolic disease.
Donna Ryan, MD, highlights exciting advancements in weight loss and metabolic treatments, particularly involving GLP-1 RAs and related therapies.
Your daily dose of the clinical news you may have missed.
Donna Ryan, MD, highlights how the media has helped to reframe obesity as a chronic disease and how antiobesity drugs are transforming metabolic disease treatment.
Donna Ryan, MD, discusses the most significant clinical trials published this year in the field of obesity medicine.